Who is sponsoring NCT03721588?

NCT03721588 is sponsored by Bozyaka Training and Research Hospital.

What drugs are being tested in NCT03721588?

Interventions in NCT03721588: Clinical interviews, psychometric scales were applied..

What condition does NCT03721588 study?

NCT03721588 studies Depressive Disorder, Major, Adult Attention Deficit Hyperactivity Disorder, Suicide.

Is NCT03721588 still recruiting?

NCT03721588 is currently completed. Last updated 30 October 2018.

Last reviewed 2018-10-30 · How we verify

NCT03721588

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD

Completed Last updated 30 October 2018

What this trial tests

trial testing Clinical interviews, psychometric scales were applied. in Depressive Disorder, Major in 96 participants. Completed in 1 September 2017.

Timeline

1 September 2015

Primary endpoint
1 June 2017

1 September 2017

Quick facts

Lead sponsor	Bozyaka Training and Research Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	96
Start date	1 September 2015
Primary completion	1 June 2017
Estimated completion	1 September 2017

Drugs / interventions tested

Clinical interviews, psychometric scales were applied.

Conditions studied

Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
Adult Attention Deficit Hyperactivity Disorder — all drugs for Adult Attention Deficit Hyperactivity Disorder →
Suicide — all drugs for Suicide →

Sponsor

Bozyaka Training and Research Hospital

Who can join

Adults 18 to 65, any sex, with Depressive Disorder, Major or Adult Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the presence of attention deficit hyperactivity disorder (ADHD) together with additional psychiatric diseases, the treatment process and prognosis of both ADHD and psychiatric comorbidity are adversely affected. The aim of this study is to compare the characteristics concerning the suicidal behavior of the patients with major depressive disorder (MDD) who have (ADHD+) or do not have (ADHD-) adult ADHD comorbidity and their responses to depression treatment. 96 inpatients were included in the study. Socio-demographic data form, Hamilton Depression Scale (HDRS), Wender Utah Rating Scale (WURS), Adult ADD/ADHD DSM IV- Based Diagnostic Screening and Rating Scale (A-ADHD), Personal and Social Performance Scale (PSP) were applied to the cases. In the study, depression starts at an early age in individuals with comorbid ADHD and the depression treatment progress changes negatively. This group of patients is at greater risk in terms of suicidal behavior. For these reasons, clinicians should be careful during ADHD and depression management in adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of clinical and suicidal behavior characteristics among urban, Turkish middle-age depressive patients with comorbid attention deficit hyperactivity disorder.
Delibas DH, Erdogan E, Gulseren S. · · 2019 · cited 4× · PMID 31896868 · DOI 10.4103/psychiatry.indianjpsychiatry_448_18

Verify or expand the search:

Other recruiting trials for Depressive Disorder, Major

Currently open trials in the same condition.

NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting

Other Bozyaka Training and Research Hospital trials

Trials by the same sponsor.

NCT06996977 — Menstrual Cycle and Postanesthetic Shivering · not yet recruiting
NCT06984653 — Effect of Scalp Block on Bispectral Index Values During Skull Pinning · completed
NCT06759506 — Can Perfusion Index and Cerebral Oxygen Saturation Trends Predict Low Cardiac Output in Pediatric Cardiovascular Surgeri · not yet recruiting
NCT06430918 — Neuropathic Pain and it's Relation to Sleep Quality in Knee Osteoarthritis · enrolling by invitation
NCT06029413 — Myo vs. Myofascial Injection for Myofascial Trigger Points · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03721588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bozyaka Training and Research Hospital
Last refreshed: 30 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03721588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing